is one of the major components of smooth muscle. Currently it is impossible to easily distinguish the two major smooth muscle (sm) forms of Tm at a protein level by immunohistochemistry due to lack of specific antibodies. ␣ -sm Tm contains a unique 2a exon not found in any other Tm. We have produced a polyclonal antibody to this exon that specifically detects ␣ -sm Tm. We demonstrate here the utility of this antibody for the study of smooth muscle. The tissue distribution of ␣ -sm Tm was shown to be highly specific to smooth muscle. ␣ -sm Tm showed an identical profile and tissue colocalization with ␣ -sm actin both by Western blotting and immunohistochemistry. Using lung as a model organ system, we examined the developmental appearance of ␣ -sm Tm in comparison to ␣ -sm actin in both the mouse and human. ␣ -sm Tm is a late-onset protein, appearing much later than actin in both species. There were some differences in onset of appearance in vascular and airway smooth muscle with airway appearing earlier. ␣ -sm Tm can therefore be used as a good marker of mature differentiated smooth muscle cells. Along with ␣ -sm actin and sm-myosin antibodies, ␣ -sm Tm is a valuable tool for the study of smooth muscle. 
S mooth muscle controls the contraction and tone of large and small blood vessels, airways, gut, and stomach. It is a complex structure composed of many different proteins including smooth-muscle-specific isoforms of actin and myosin, calponin, caldesmon, SM22 ␣ , calmodulin, and tropomyosin. Many of these are used as markers for smooth-muscle-cell phenotype in developmental studies and in studies of smooth-muscle-cell phenotypic modulation where the expression of these proteins can be altered (Owens 1995; Low and White 1998) .
Tropomyosins (Tm) are rod-like helical proteins that dimerize and bind to actin. In smooth muscle cells, Tm is likely to play a role in the stabilization of the smooth muscle actin contractile filaments, similar to its role in non-muscle cells. The four Tm genes produce many isoforms (Ͼ40) as a result of alternative exon usage. Most are found in non-muscle cells, but there are some specific to either striated or smooth muscle. Only two isoforms appear to be specific to smooth muscle-one from the ␤ Tm gene and the other from the ␣ Tm gene. ␣-sm Tm contains a unique exon 2a, not found in any other Tm, whereas ␤-sm Tm uses the same 2b exon as muscle isoforms ( Figure  1 ). No specific antibody exists to either of the two smooth muscle isoforms of Tm, although other antibodies can detect them both but these also detect other non-muscle or striated muscle isoforms, making them unable to be used to label smooth muscle specifically. Tropomyosin has not previously been widely studied in smooth muscle when compared with actin and myosin, partly due to a lack of specific antibodies (Owens 1995) .
We have developed an antibody to exon 2a that is specific for the ␣-sm Tm isoform and we demonstrate here its utility. Using this antibody, we have demon-Vrhovski, McKay, Schevzov, Gunning, Weinberger strated for the first time the specific localization and distribution of a single smooth-muscle-specific isoform of Tm. Using lung as a model system, we have examined the developmental profile of this Tm in comparison to actin and showed that this antibody can be used as a marker for differentiated mature smooth muscle tissues.
Materials and Methods

Antibodies
To produce a polyclonal antibody specific for ␣ -sm Tm, a synthetic peptide corresponding to exon 2a from the ␣ Tm (TPM1) rat gene was made (Ruiz-Opazo and Nadal-Ginard 1987) . The peptide was synthesized (Mimotopes; Melbourne, Australia) with a cysteine residue at the N terminus to facilitate conjugation to diphtheria toxoid. Two-mg peptide was injected into a sheep in three doses over 12 weeks following a standard protocol from the Institute for Medical and Veterinary Sciences, Veterinary Services Division (Adelaide, Australia). Five ml of total bleed-out serum was affinity purified through a Sepharose column with peptide attached (Mimotopes) to produce affinity-purified polyclonal antibody. The concentration of the purified antibody ( ␣ 2a) was 0.3 mg/ml and was used at 1/100 dilution for both Western blotting and immunochemistry.
CG3 monoclonal antibody used at 1/500 dilution recognizes an epitope in the 1b exon of the ␥ Tm (TPM3) gene (Novy et al. 1993) and was a gift from Dr. Jim Lin (University of Iowa; Iowa City, Iowa). ␣ -sm Actin antibody (Sigma; St Louis, MO) was used at 1/500 dilution. Horseradish peroxidase (HRP)-conjugated donkey anti-mouse (Amersham; Buckinghamshire, UK) and donkey anti-sheep (Jackson ImmunoResearch; West Grove, PA) were used at 1/10,000. Alkaline phosphatase-conjugated secondaries (donkey antisheep and goat anti-mouse) were from Jackson ImmunoResearch and were used at 1/1000.
Tissue Preparation for Western Blotting
Whole tissues were removed from wild-type FVB strains of adult mice and immediately frozen in liquid nitrogen. Stomach and intestine were opened and rinsed with phosphatebuffered saline (PBS) prior to freezing. Tissues were homogenized in 50 mM Tris-Cl, pH 8.0, in a volume adequate to cover the tissue, using a Polytron blender. Samples of whole tissue homogenate were diluted half in solubilization buffer (100 mM Tris-Cl, pH 7.6, 2% SDS, 2 mM DTT) and then quantified using a BCA protein assay kit (Pierce; Rockford, IL). Twenty-g samples were analyzed by 15% SDS-PAGE.
Tissue Preparation for Immunohistochemistry
Embryos from various stages of development and whole tissues from adult mouse were removed and fixed in 10% formalin before embedding in paraffin wax. Lungs from 1-and 7-day-old postnatal and adult mice were perfused with 10% formalin to inflate the airways by gravity flow from a height of 20 cm by cannulation of the trachea. The trachea was then tied off with suture cotton and the inflated lungs placed in 10% neutral-buffered formalin for 1 week before embedding in paraffin. Tissue sections were cut at 5 m and placed onto a poly-l -lysine-coated slide (Menzel-Glaser; Braunscheig, Germany). Consecutive sections were used for staining.
Human lung tissue was obtained at coronial postmortem. Ethics approval was obtained from the Children's Hospital at Westmead Ethics Committee and written consent for use in research was obtained from the next of kin. Tissues were obtained from 4-month-old, 2-year-old, and 9-year-old females. The causes of death were unrelated to lung disease, although the 9-year-old female showed signs of inflammation and smooth muscle thickening consistent with undiagnosed, untreated chronic asthma. The other two samples showed no signs of lung pathology. The tissues were fixed by immersion in 10% neutral-buffered formalin and random samples were processed into paraffin blocks and sectioned onto slides. Several consecutive sections were used for staining. Human tissue for Western blotting was treated essentially as described for the mouse tissues.
Immunohistochemistry
Slides were dewaxed in xylene/ethanol, washed in PBS, and blocked in 10% fetal calf serum for 10 min. Primary antibody diluted in PBS was applied for 3 hr. Slides were washed in PBS and secondary antibody applied at 1/1000 dilution for 1 hr. Immunoreactivity was visualized by nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Roche Diagnostics; Sydney, Australia) for ‫ف‬ 45 min. Sections were counterstained with nuclear fast red and dehydrated in ethanol/ xylene before coverslipping.
Western Analysis
Gels were blotted at 80 V for 2 hr onto PVDF (Millipore; Bedford, MA) and blocked overnight at 4C in 5% skim milk powder. Blots were washed in Tris-buffered saline (100 mM Tris, pH 7.5, 150 mM NaCl; TBS) for 5 min and primary antibody applied in TBS for 2 hr with gentle agitation. Blots were washed in TBS/0.5% Tween 20 (TTBS) four times for 15 min each. HRP-conjugated secondary antibody was applied for 1 hr, followed by four 20-min washes with TTBS. Western lightning chemiluminescent reagent (Perkin Elmer Life Sciences; Norwalk, CT) was used according to manufacturer's instructions. Signal was visualized on X-ray film after exposures of between 2 and 60 min.
Results
We made a polyclonal antibody directed against the 2a exon from the ␣ tropomyosin gene (Figure 1 ). This exon is specific for the smooth muscle isoform from this gene and is not found in other Tms from this gene or in other smooth muscle Tms such as Tm1, which is from the ␤ gene (Figure 1) .
To characterize the ␣ -sm Tm isoform antibody, its expression and tissue distribution was analyzed by Western blotting. Figure 2A shows adult mouse tissues incubated with our ␣ /2a Tm antibody. The antibody detected a band of expected size of 40 kDa in tissues known to have high levels of smooth muscle, such as lung, intestine, stomach, and aorta, as well as significant amounts in kidney, and on a much longer exposure a faint band could also be detected in the heart (data not shown) as predicted from the RT-PCR results of Muthuchamy et al. (1993) . Longer exposures did not, however, reveal the presence of the 34-kDa ␣/2a containing Tm reported by Zajdel et al. (2002) and Denz et al. (2004) in axolotl and human hearts suggesting that if expressed in mouse it is below the level of detection with this antibody. An extra band of larger size was seen in the aorta. When these were incubated in the presence of the ␣/2a peptide, all 40-kDa bands were absent but this larger band in aorta was still present, indicating it is probably a nonspecific background band. Some degradation of actin was apparent in the stomach samples but this was not seen with Tm. When compared with the ␣-sm actin antibody, the pattern is similar. It therefore appears that both ␣-sm actin and ␣-sm Tm are coexpressed in the same tissues, but the relative level of expression of ␣-sm Tm between organs differs to that seen with ␣-sm actin, especially for the aorta, suggesting that the stoichiometry of ␣-sm Tm to ␣-sm actin may be different. Staining with CG3, which detects non-muscle isoforms from the ␥ Tm gene, is shown as a control (Figure 2A ). The expression is quite different and more widespread than for ␣/2a. The ␣/2a antibody also recognizes the same protein in human lung. Figure 2B shows reactivity of this antibody with a 39-kDa protein in human lung. The small difference in mobility between mouse and human may reflect a conformational difference based on five amino acid differences.
Tissue-specific localization of ␣-sm Tm was checked by immunohistochemistry. In all adult mouse tissues examined, ␣-sm actin and ␣-sm Tm show absolute colocalization when adjacent sections are stained. Figures 3A and 3E show examples of lung, stomach (Figures 3B and 3F) , intestine (Figures 3C and 3G) , and esophagus ( Figures 3D and 3H ). In all cases the smooth muscle was labeled specifically with the ␣-sm actin and ␣ /2a antibodies and no other cell types were labeled, although there is slight epithelial staining in esophagus with ␣ /2a not seen with ␣ -sm actin.
Smooth Muscle in Lung Development
Due to the presence of both airway and blood vessel smooth muscles within the lung, we chose to examine this organ in further detail. The expression of ␣ -sm Vrhovski, McKay, Schevzov, Gunning, Weinberger Tm was examined in developing lung and compared with ␣ -sm actin and the unrelated CG3 antibody to identify ␥ Tm gene products. Whole lung from 2-and 7-day-old newborn and adult mice were compared. Western blot analysis (Figure 4 ) clearly showed that ␣ -sm Tm expression was significantly lower on postnatal days 2 and 7 lung than adult, whereas ␣ -sm actin showed high-level expression at all three time points. Figure 5 compares immunohistochemical staining in sections of lung from different ages. In adult, ␣ -sm actin ( Figure 5A ) and ␣ -sm Tm ( Figure 5B ) colocalized and stained both airway and blood vessel smooth muscle equally well, although ␣ /2a staining was fainter than ␣ -sm actin. In lung from 7-day-old mouse, the airway and blood vessel again stained equally well with ␣ -sm actin ( Figure 5C ) but ␣ /2a ( Figure 5D ) stained blood vessel smooth muscle more faintly than airway smooth muscle when compared with actin ( Figure 5C ). Large blood vessels, however, are not stained at all with ␣ /2a antibody but are well stained with actin (arrow, Figures 5C and 5D ). Prenatal lung tissue was also examined to investigate the time course of appearance of detectable ␣ -sm Tm and actin during development. Two developmental time points were studied-embryonic day 17.5 ( Figures 5E and 5F ) and embryonic day 15.5 ( Figures 5G and 5H ). At both these times staining of lung sections revealed the presence of ␣ -sm actin (Figures 5E and 5G) in both airways and blood vessels but no detectable ␣ -sm Tm ( Figures 5F and 5H) . Interestingly, extrapulmonary blood vessels did show some detectable staining for ␣ -sm Tm ( Figures 5J and 5K ) although the staining was less intense than for ␣ -sm actin ( Figure 5I ). It appeared that there was more detectable ␣ -sm Tm in smaller blood vessels ( Figure 5K ) in comparison to larger blood vessels ( Figure 5J ). Other types of smooth muscle, such as in the gut wall, stained for ␣ -sm Tm at both embryonic days 17.5 (not shown) and 15.5 (Figure 5M) , although with less intensity than ␣ -sm actin 
and adult. ␣-sm Actin is already very high at PD2 and does not change with development. In contrast, ␣-sm Tm is very low at both PD2 and PD7 but has increased in the adult. CG3 shows the levels of unrelated tropomyosin from the ␥ gene for comparison and shows no obvious developmental changes.
( Figure 5L ), indicating that some tissues are producing this Tm at high levels but lung is not.
Human Lung
Because the antibody also recognizes the corresponding human protein, we examined human lung tissue to determine the usefulness of this antibody for human histopathology. Figure 6 shows comparisons of human lung from a 9-year-old female stained with ␣-sm actin ( Figures 6A and 6E ) and ␣/2a Tm ( Figures 6B  and 6F ). It is obvious from the staining shown in Figure 6 that the ␣/2a Tm antibody works well on human tissue and colocalizes with all ␣-sm actin staining. It stains airway and blood vessel smooth muscle with good intensity. However, the ␣/2a tropomyosin antibody seems to also stain collagen-containing connective tissue surrounding the large elastic arteries and between airways and blood vessels ( Figures 6B and  6F ). Gomori trichrome staining ( Figures 6C and 6G) demonstrates collagenous tissues by aqua-green staining. It is unclear why this connective tissue stains; however, the Western blot of human lung with this antibody shows only a single band ( Figure 2B ). Because the lung tissue shown in Figure 6 was from a 9-year-old subject where lung development is nearing completion, lung samples from younger subjects were examined to see if ␣-sm Tm expression in human lung paralleled that found in the mouse. Staining for ␣-sm Tm in lung samples from a 2-year-old ( Figures  7A and 7B ) and 4-month-old ( Figures 7C and 7D ) Figure 5 Immunohistochemistry of adult mouse lung tissues stained with ␣-sm actin and ␣/2a (blue/purple). Both AW and BV smooth muscle in adult lung is stained by both actin (A) and ␣/2a (B), although both AW and BV appear slightly less intense with ␣/2a. In the 7-day-old mice lung, ␣-sm actin stains both AW and BV equally well (C), whereas ␣/2a only stains the AW (D). However, at embryonic day (ED) 17.5 (E,F) and 15.5 (G,H) actin stains smooth muscle in lung tissue well (E,G), whereas ␣/2a shows little discernible staining at all (arrows in F,H). At ED 17.5, larger blood vessels outside the lung are only faintly stained with ␣/2a (J), whereas actin staining is still strong (I). Smaller blood vessels are well stained with ␣/2a (K). Similarly, even at ED 15.5, smooth muscle in the gut is stained by both actin (L) and ␣/2a (M), although more faintly.
were therefore analyzed. ␣-sm Actin antibody stained smooth muscle in airways and blood vessels equally well at both age points, but ␣/2a only stained the 2-year-old lung ( Figure 7B ) but not the 4-month-old ( Figure 7D ). Tm staining was also not identical to actin in the 2-year-old sample with some smaller blood vessels not staining. Collagen staining was still evident in both age groups.
Discussion
We have successfully made a polyclonal antibody that specifically detects one isoform of Tm from the ␣ gene. This is the first time such an antibody has been reported and is likely to be of importance in studies of smooth muscle development and modulation during aging and disease. This smooth-muscle-specific Tm isoform is the only one of many isoforms to be pro- Figure 6 Human lung sections from a 9-year-old female, stained with ␣-sm actin (A,E), ␣/2a (B,F), Gomori trichrome (C,G), and hematoxylin and eosin (D,H). AW and BV stain equally well with both ␣-sm actin and ␣/2a. However, ␣/2a also stains the connective tissue containing collagen surrounding smooth muscle (green in C,G).
duced from this gene that contains the 2a exon. The only other Tm isoform found in smooth muscle is from the ␤ gene that does not contain a 2a exon or show any homology to the 2a exon from the ␣ gene. From the available genomic DNA sequences for tropomyosin, no other exons homologous to 2a are found in either the ␥, ␦, or ␤ tropomyosin genes of human or mouse. PCR analysis of transcripts from the ␣ gene using a variety of tissues indicates that many 2a-containing transcripts should exist (Cooley and Bergtrom 2001) in most tissues. However, it is not known if any of these are high-level transcripts or if any are expressed as proteins. From our Western blotting results, only those tissues known to contain significant amounts of smooth muscle actually reacted with the antibody to any extent showing a similar pattern to that seen with ␣-sm actin. These results are consistent with McHugh et al. (1991) who showed a similar result with ␣-sm actin antibody only reacting with similar tissues. In contrast, brain and liver have little detectable 2a protein although they have an amplifiable 2a-containing transcript, implying transcripts are at low levels or are not translated (Cooley and Bergtrom 2001) . This pattern is consistent with that for ␣-sm actin. A similar study demonstrated that kidney, liver, and brain had extremely low levels of ␣-sm actin mRNA at birth and early postnatally, but no levels of ␣-sm actin mRNA were demonstrated in adult tissues (McHugh and Lessard 1988) . The results from this study show that the presence of ␣-sm actin and Tm is likewise either very low or undetectable under our conditions in these adult tissues. Because ␣/2a is high in blood vessels, the transcripts detected by Cooley and Bergtrom (2001) may actually come from vascular tissue in these organs. Recently, a novel cardiac-specific Tm containing the 2a exon from the ␣-gene was detected in human heart using PCR amplification (Denz et al. 2004 ) and has also been detected in axolotl heart (Zajdel et al. 2002) . This isoform contains the 9a/9b C terminus like striated Tm but with 2a in place of 2b. This was not demonstrated by direct protein visualization due to lack of a suitable antibody and was not examined in mouse or rat heart. Our ␣/2a antibody may be able to detect this novel isoform if present in sufficient quantity although, in our Western blot, heart from mouse did not appear to have a detectable band.
In all tissues examined, only one band was detected that was completely inhibited by addition of peptide as a competitor for the antibody. The staining pattern on histological samples could similarly be inhibited by the peptide (not shown). In organs such as brain and liver, the only positive staining detectable by immunohistochemistry was in blood vessels (not shown) with extended incubations only resulting in much background nonspecific staining. In contrast, our antibody shows a clear preference for smooth muscle structures in lung, gut, stomach, and esophagus, colocalizing with smooth muscle actin. The tight coexpression of ␣-sm Tm and actin is consistent with the possibility that these isoforms may have a preferred association in the microfilaments of smooth muscle cells. We con- clude that the ␣/2a antibody specifically recognizes a single form of tropomyosin found in smooth muscle and that it will be particularly useful in investigations of smooth muscle biology and pathophysiology.
Tropomyosin in the Lung
The developmental process in lung is well studied, so we chose to use lung as our model for ␣-sm Tm expression. It is clear that in the mouse ␣-sm Tm is a protein that appears later in development than ␣-sm actin. Whereas ␣-sm actin appears at a high level from the earliest postnatal samples, ␣-sm Tm was just detectable at younger embryonic ages but increases in adult lung as shown by Western blotting. From immunohistochemical data, ␣-sm Tm does not appear to be expressed in significant quantities in the lung for protein detection until embryonic day 15.5, although mRNA is reported as detectable in embryonic stem cells and embryoid bodies (Muthuchamy et al. 1993 ). We were unable to detect expression in skeletal muscle or cardiac muscle at any time. ␣-sm Tm protein was detected only in smooth muscle. The onset of expression appears to depend on tissue type, with intestine expressing early in development and lung quite late. This fits with the normal pattern of development because the lung is the last organ to mature prenatally and is embryologically derived from the gut. Indeed, the lung continues to develop postnatally and is not structurally mature until somewhere between the third and eighth year of life in humans. Results from the mouse correlate well with human, insofar as very little ␣-sm Tm is seen in human lung samples from a 4-month-old child. Interestingly, there were differences in onset of expression for lung airway smooth muscle and lung vascular smooth muscle. Other markers of smooth muscle show these differences also, such as calponin and actin, where expression is earlier in systemic blood vessels than pulmonary (Jostarndt-Fogen et al. 1998) . ␣-sm Actin is the earliest known marker of smooth-muscle-cell differentiation McHugh 1995) but is not necessarily the most specific, because ␣-sm actin is transiently expressed in both cardiac and skeletal muscle (Woodcock-Mitchell et al. 1988; McHugh 1995) . As early as 10 weeks gestation, human lung shows ␣-sm actin positive staining ). Other markers of smooth muscle such as myosin heavy chain, vimentin, calponin, caldesmon, and desmin exist Halayko et al. 1996; Low and White 1998) . A number of different isoforms of smooth muscle myosin heavy chain exist and, interestingly, these can be found in different cellular regions. For example, larger elastic arteries do not contain the smooth myosin-B isoform but airways and small blood vessels do (Low et al. 1999) . It may be that ␣-sm Tm is preferentially associated with a particular myosin isoform, because some heterogeneity is also noted with ␣-sm Tm staining. Indeed, a recent study has demonstrated that manipulation of Tm isoform composition of neuroepithelial cells can alter myosin recruitment to actin filaments (Bryce et al. 2003) . In studies thus far, ␤-sm Tm and ␣-sm Tm are thought to be present in approximately equal amounts (Fatigati and Murphy 1984) , and it is thought that they dimerize. However, it has not been demonstrated that the two isoforms colocalize in all tissues. A ␥-smooth muscle isoform of actin also exists as well as the ␣-smooth muscle isoform and there may be differences in the distribution of ␣-and ␤-sm Tm and their correlation with these actin isoforms. This may explain the difference in intensity we found with ␣-sm actin and ␣-sm Tm in aorta when compared with the other tissues. Using the existing nonspecific antibodies with ␣/2a may help shed light on isoform distribution and whether any switching occurs during development, analogous to that seen in brain development (Weinberger et al. 1996; Schevzov et al. 1997; Hannan et al. 1998) . Indeed, there is a growing body of evidence to suggest that many different cell types sort tropomyosin isoforms into spatially segregated actin populations in brain (Gunning et al. 1998a,b) , fibroblasts (Percival et al. 2000 (Percival et al. ,2004 , epithelial cells (Dalby-Payne et al. 2003) , and skeletal muscle (Kee et al. 2004) .
Smooth muscle myosin heavy chain is highly specific for the smooth muscle lineage in development (Miano et al. 1994; Owens 1995; Jostarndt-Fogen et al. 1998; Ratajska et al. 2001) , but due to its later appearance ␣-sm Tm may be a better marker for fully differentiated smooth muscle especially in adult tissues and may be used to assess the degree of differentiation of vascular smooth muscle. The use of Tm as a marker for smooth muscle has not been possible until now due to a lack of specific antibodies. The ␣/2a antibody colocalizes with ␣-sm actin and can be used as a marker for differentiated smooth muscle in both human and mouse tissues. It may therefore potentially be useful for analysis of pathological states involving smooth muscle, such as in asthma where smooth muscle hypertrophy occurs, as well as in monitoring smooth muscle cell phenotypic modulation in cultured cells.
